Nectar Lifesciences corrects AGM cut-off date error in revised proceedings
- Nectar Lifesciences issued revised AGM proceedings to correct a cut-off date error
- Shareholders approved FY26 financials and reappointed key board members
- Promoter group voted 100% in favour of all five resolutions
- Statutory auditors gave unqualified opinion on FY25-26 results
*this image is generated using AI for illustrative purposes only.
Nectar Lifesciences has issued revised proceedings for its 31st annual general meeting (AGM) held on September 18, 2026. The update corrects an inadvertent error regarding the cut-off date for voting eligibility. Shareholders had previously approved the company’s standalone and consolidated financial statements for FY26 during the meeting.
The revised disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Company Secretary Sanjaymohan Singh Rawat signed the letter dated September 19, 2026, enclosing the corrected proceedings. The original cut-off date for voting eligibility is confirmed as Friday, September 11, 2026.
Voting Results
The Consolidated Scrutinizer's Report confirmed that all five resolutions passed with the requisite majority. A total of 133 members cast their votes through remote e-voting and instant polling during the AGM. The promoter group, holding 100,706,448 shares (51.84% of total shares), voted 100% in favour of all resolutions.
| Resolution | Votes Polled | In Favour | Against | % In Favour |
|---|---|---|---|---|
| Adoption of Financial Statements | 101,660,738 | 101,646,467 | 14,271 | 99.99% |
| Reappointment of Sanjiv Goyal | 101,660,738 | 101,626,376 | 34,362 | 99.97% |
| Reappointment of Dr. Kuldip Kumar Bhasin | 101,660,738 | 101,626,376 | 34,362 | 99.97% |
| Reappointment of Dr. Indu Pal Kaur | 101,660,738 | 101,626,376 | 34,362 | 99.97% |
| Appointment of Dr. Gunmala Suri | 101,660,738 | 101,626,376 | 34,362 | 99.97% |
Public institutional investors also voted unanimously in favour of all resolutions. Among public non-institutional investors, support ranged from 46.82% to 77.91% depending on the resolution, though the promoter block ensured passage in all cases.
Audit and Governance
Statutory auditors M/s. Deepak Jindal & Co., Chartered Accountants, and secretarial auditors P. Chadha & Associates expressed an unqualified opinion on the financial year 2025-26 results. No qualifications or adverse comments were noted in the audit reports regarding the company’s functioning or financial statements.
Board Appointments
The following resolutions were passed during the ordinary and special business segments:
| Director | Role | Action |
|---|---|---|
| Sanjiv Goyal | Chairman & Managing Director | Reappointed by rotation |
| Dr. Kuldip Kumar Bhasin | Independent Director | Reappointed for second term |
| Dr. Indu Pal Kaur | Independent Director | Reappointed for second term |
| Dr. Gunmala Suri | Non-Executive Non-Independent Director | Appointed |
Chairman Sanjiv Goyal thanked members for their trust and acknowledged the commitment of the company’s workforce. The meeting concluded at 11:25 am.
Historical Stock Returns for Nectar Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.23% | +1.86% | -14.24% | -3.43% | -27.13% | -67.44% |
How might the reappointment of key directors and the addition of Dr. Gunmala Suri influence Nectar Lifesciences' strategic direction for FY27?
What specific growth initiatives or R&D projects are likely to be prioritized following the unqualified audit opinion and approval of FY26 financials?
Could the variance in voting support among public non-institutional investors (46.82% to 77.91%) signal emerging concerns about corporate governance or dividend policy?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
